Inviragen’s DENVax vaccine, developed by researchers at the CDC’s Division of Vector-Borne Diseases, is based on an attenuated DEN-2 virus that generates long-lasting anti-dengue immune responses.
The Colombian Phase 1 trial will measure the safety of DENVax as well as the immune responses induced by the vaccine in healthy adults.
DENVax is also being studied in an ongoing US Phase 1 trial that commenced in May 2010
In Inviragen’s Colombian Phase 1 study, an estimated 112 healthy adult volunteers will receive injections of a placebo or two doses of the investigational DENVax vaccine.
However, the US Phase 1 trial will investigate the safety and immune responses after both subcutaneous and intradermal delivery of DENVax.
Inviragen chief scientific officer Jorge Osorio said that the trial will determine whether DENVax is safe and immunogenic in patients who live in endemic countries such as Colombia and can ultimately benefit from the vaccine.